Hoth Competitors

Stocks . USA . 
Stock . Hoth Therapeutics
HOTH Stock  USD 1.02  0.04  4.08%   
Hoth Therapeutics competes with Curis, Briacell Therapeutics, Palisade Bio, Processa Pharmaceuticals, and Aspire BioPharma; as well as few others. The company conducts business under Pharmaceuticals sector and is part of Health Care industry. Analyzing Hoth Therapeutics competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Hoth Therapeutics to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Hoth Therapeutics Correlation with its peers.
For more detail on how to invest in Hoth Stock please use our How to Invest in Hoth Therapeutics guide.

Hoth Therapeutics vs Entero Therapeutics Correlation

Very good diversification

The correlation between Hoth Therapeutics and ENTO is -0.23 (i.e., Very good diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Hoth Therapeutics and ENTO in the same portfolio, assuming nothing else is changed.

Moving against Hoth Stock

  0.76VTRS Viatris Sell-off TrendPairCorr
  0.73SFZN Siegfried Holding Earnings Call This WeekPairCorr
  0.73C43 Cosmo PharmaceuticalsPairCorr
  0.67ELAN Elanco Animal HealthPairCorr
  0.66TEV Teva PharmaceuticalPairCorr
Specify up to 10 symbols:
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Hoth Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
0.050.984.78
Details
Intrinsic
Valuation
LowRealHigh
0.101.955.75
Details

Hoth Therapeutics Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Hoth Therapeutics and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Hoth and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Hoth Therapeutics does not affect the price movement of the other competitor.

High positive correlations

PULM
+ 0.89
PCSA
PULM
+ 0.87
LEXX
LEXX
+ 0.85
PCSA
BCTX
+ 0.76
CRIS
ASBP
+ 0.72
PALI
PULM
+ 0.67
CRIS
  

High negative correlations

ENTO
- 0.67
ASBP
ENTO
- 0.53
BCTX
ENTO
- 0.43
PALI
ENTO
- 0.4
CRIS
FBLG
- 0.31
CRIS
ENTO
- 0.23
PCSA

Risk-Adjusted Indicators

There is a big difference between Hoth Stock performing well and Hoth Therapeutics Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Hoth Therapeutics' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
CRIS  4.16 (0.17) 0.00 (0.02) 0.00 
 0.00 
 10.62 
(8.13)
 33.70 
BCTX  6.43 (0.87) 0.00 (0.61) 0.00 
 0.00 
 13.53 
(8.91)
 98.43 
PALI  5.44 (0.05) 0.00  0.16  0.00 
 0.00 
 10.53 
(10.26)
 31.35 
PCSA  8.33 (0.45) 0.00  0.83  0.00 
 0.00 
 10.24 
(14.08)
 164.28 
ASBP  7.77 (0.89) 0.00  2.24  0.00 
 0.00 
 19.52 
(16.05)
 66.08 
LEXX  5.32 (0.59) 0.00 (0.30) 0.00 
 0.00 
 9.23 
(9.68)
 42.53 
FBLG  5.91 (0.13) 0.00 (0.08) 0.00 
 0.00 
 14.71 
(12.82)
 47.13 
PULM  3.43 (0.83) 0.00  1.05  0.00 
 0.00 
 6.62 
(5.75)
 51.95 
DARE  2.94 (0.06) 0.00 (0.03) 0.00 
 0.00 
 5.31 
(6.98)
 26.52 
ENTO  8.13 (0.04) 0.00  0.32  0.00 
 0.00 
 19.74 
(17.06)
 39.61 

Hoth Therapeutics Competitive Analysis

The better you understand Hoth Therapeutics competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Hoth Therapeutics' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Hoth Therapeutics' competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
HOTH CRIS BCTX PALI PCSA ASBP LEXX FBLG PULM DARE
 4.08 
 1.02 
Hoth
 6.48 
 1.15 
Curis
 0.73 
 4.07 
Briacell
 0.57 
 1.73 
Palisade
 3.06 
 2.22 
Processa
 9.16 
 1.43 
Aspire
 3.13 
 0.62 
Lexaria
 3.85 
 0.25 
FibroBiologics
 0.81 
 2.44 
Pulmatrix
 1.16 
 1.70 
Dare
Market Volatility
(90 Days Market Risk)
Very risky
Risky
Somewhat reliable
Risky
Dangerous
Extremely Dangerous
Out of control
Extremely Dangerous
Risky
Unstable
Market Performance
(90 Days Performance)
Weakest
Weakest
Weakest
Weakest
Weakest
Weakest
Weakest
Weakest
Weakest
Weakest
Odds of Financial Distress
(Probability Of Bankruptcy)
Small
Risky
Risky
High
Risky
High
Low
Risky
Risky
Strong
Current Valuation
(Equity Enterprise Value)
Under Valued
Under Valued
Under Valued
Under Valued
Under Valued
Over Valued
Over Valued
Under Valued
Under Valued
Under Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Strong Buy
Strong Buy
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Buy
Strong Buy
Strong Buy
Hold
Hold
Not Rated
Strong Hold
Buy
Cautious Hold
Strong Buy
Current Ratio
15.74
7.69
45.0
2.59
8.89
N/A
40.09
N/A
8.19
2.17
Net Asset
7.71 M
41.27 M
29.77 M
10.88 M
3.23 M
147.99 K
4.18 M
16.45 M
9.94 M
22.1 M
EBITDA
27.13 K
(42.57 M)
(36.63 M)
(14.42 M)
(12.05 M)
(11.65 M)
(11.8 M)
(10.57 M)
(7.04 M)
(23.41 M)
Current Valuation
6.71 M
6.88 M
15.4 M
254.6 M
(1.17 M)
13.14 M
11.55 M
19.19 M
(645.95 K)
4.51 M
Price To Book
1.77
4.32
2.55
80.88
0.88
N/A
3.23
135.54
1.88
8.62
Operating Margin
N/A
-2.18
N/A
N/A
N/A
-590.16
-20.15
N/A
N/A
N/A
Retained Earnings
(60.41 M)
(1.24 B)
(153.65 M)
(135.94 M)
(87.22 M)
(2.78 M)
(63.46 M)
(35.52 M)
(297.16 M)
(175.29 M)
Current Asset
448.84 K
85.5 M
N/A
N/A
N/A
N/A
N/A
N/A
8.34 M
7.58 M
Beta
0.54
3.07
2.03
1.61
1.02
0.81
0.52
-0.58
1.71
0.95
Number Of Employees
2
34
N/A
8
10
4
7
13
2
21
Shares Outstanding
15.51 M
12.93 M
6.21 M
149 M
2.27 M
4.79 M
24.89 M
66.52 M
3.65 M
14.29 M
Cash Flow From Operations
(6.98 M)
(39.56 M)
(39.07 M)
(12.19 M)
(11.25 M)
(265.19 K)
(10.45 M)
(11.9 M)
(10.72 M)
5.39 M
Total Debt
31.07 K
2.95 M
5.93 M
169 K
73.51 K
1.27 M
109.32 K
10.55 M
996 K
1.3 M
Return On Equity
-1.51
-29.51
-4.44
-2.29
-2.71
N/A
-1.55
-12.93
-0.79
-25.43
Return On Asset
-0.84
-0.61
-1.62
-0.88
-1.3
-1.95
-0.83
-1.16
-0.47
-0.45
Number Of Shares Shorted
783.32 K
599.1 K
142.14 K
21.1 M
29.97 K
693.75 K
631.2 K
851.74 K
4.2 K
310.4 K
Book Value Per Share
0.54
-1.15
5.3
0.35
2.76
-9.26
0.22
0.003
1.3
0.21
Current Liabilities
312.22 K
10.76 M
N/A
N/A
N/A
N/A
N/A
N/A
4.11 M
17.82 M
Total Asset
7.71 M
41.27 M
29.77 M
10.88 M
3.23 M
147.99 K
4.18 M
16.45 M
9.94 M
22.1 M
Debt To Equity
2.01
0.075
N/A
0.23
0.001
N/A
0.007
N/A
0.044
0.022
Short Ratio
1.24
0.54
0.14
3.56
0.32
0.37
2.4
0.33
0.25
3.87
Target Price
5.0
14.0
150.0
13.4
25.0
N/A
4.5
7.0
10.0
10.75
Shares Owned By Institutions
8.3
36.33
1.0
47.81
9.02
4.06
8.66
7.7
9.2
8.14
Market Capitalization
14.46 M
14.87 M
25.5 M
259.61 M
5.19 M
6.47 M
15.87 M
16.94 M
8.69 M
24.58 M
Price To Earning
-7.16
-3.21
N/A
0.16
N/A
N/A
N/A
N/A
-1.3
-43.44
Price To Earnings To Growth
N/A
N/A
N/A
N/A
-0.12
N/A
N/A
N/A
N/A
N/A
Price To Sales
N/A
1.28
N/A
14.03
N/A
3331.53
30.4
N/A
2897.48
751.51
Net Income
(8.19 M)
(43.39 M)
(36.5 M)
(14.44 M)
(11.85 M)
(1.31 M)
(11.91 M)
(11.16 M)
(9.56 M)
(4.05 M)
Earnings Per Share
-1.02
-3.54
-33.87
-2.07
-26.42
-25.66
-0.57
-0.48
-1.71
-1.83
Shares Owned By Insiders
3.57
6.99
0.6
0.02
10.76
10.84
6.1
17.85
0.66
8.73
Revenue
N/A
10.91 M
N/A
N/A
N/A
N/A
705.92 K
N/A
7.81 M
9.78 K
Working Capital
6.81 M
7.36 M
(3.81 M)
7.26 M
340.99 K
(1.54 M)
1.97 M
1.5 M
8.99 M
(3.16 M)
Cash And Equivalents
11.62 M
98.69 M
41.04 M
5 M
12.06 M
N/A
7.34 M
N/A
42.91 M
40.39 M
Cash Per Share
9.02
1.02
2.64
0.23
0.76
N/A
1.23
N/A
12.67
0.48
Gross Profit
N/A
(20.05 M)
N/A
N/A
N/A
884
522 K
N/A
(7.16 M)
(14.35 M)
Day Typical Price
1.01
1.14
4.1
1.76
2.21
1.41
0.63
0.25
2.47
1.71
Accumulation Distribution
67022.74
28648.74
7915.64
167133.0
4300.67
66209.22
7126.71
50803.67
303.79
1053.12
Market Facilitation Index
N/A
0.0
0.0
N/A
0.0
N/A
N/A
N/A
0.0
0.0
Daily Balance Of Power
0.4
0.5
(0.16)
(0.08)
(0.39)
0.5714
(0.50)
(0.33)
(0.22)
(0.33)
Period Momentum Indicator
0.04
0.07
(0.03)
(0.01)
(0.07)
0.12
(0.02)
(0.01)
(0.02)
(0.02)
Rate Of Daily Change
1.04
1.06
0.99
0.99
0.97
1.09
0.97
0.96
0.99
0.99
Day Median Price
1.01
1.14
4.12
1.78
2.21
1.4
0.63
0.26
2.49
1.72
Price Action Indicator
0.03
0.045
(0.06)
(0.06)
(0.03)
0.095
(0.02)
(0.01)
(0.06)
(0.03)
Coefficient Of Variation
(2,483)
(16,701)
(1,421)
(10,163)
(3,980)
(1,284)
(1,574)
(14,248)
(702.29)
(32,836)
Mean Deviation
2.95
4.16
6.43
5.44
8.33
7.77
5.32
5.91
3.43
2.94
Jensen Alpha
(0.23)
(0.17)
(0.87)
(0.05)
(0.45)
(0.89)
(0.59)
(0.13)
(0.83)
(0.06)
Total Risk Alpha
(0.45)
(0.47)
(1.62)
(0.58)
(1.89)
(1.78)
(1.06)
(0.76)
(1.33)
(0.34)
Standard Deviation
3.81
5.78
11.16
6.79
18.87
11.6
7.61
9.25
6.11
4.21
Kurtosis
0.5003
1.19
11.63
(0.36)
31.43
4.32
5.48
3.99
19.05
4.96
Potential Upside
5.83
10.62
13.53
10.53
10.24
19.52
9.23
14.71
6.62
5.31
Treynor Ratio
(0.15)
(0.02)
(0.61)
0.16
0.8337
2.24
(0.30)
(0.08)
1.05
(0.03)
Maximum Drawdown
13.03
33.7
98.43
31.35
164.28
66.08
42.53
47.13
51.95
26.52
Variance
14.52
33.4
124.44
46.13
355.94
134.67
57.84
85.55
37.31
17.72
Market Risk Adjusted Performance
(0.14)
(0.01)
(0.60)
0.17
0.8437
2.25
(0.29)
(0.07)
1.06
(0.02)
Risk Adjusted Performance
(0.02)
0.0038
(0.05)
9.0E-4
(0.01)
(0.05)
(0.04)
0.0035
(0.11)
0.0056
Skewness
0.2626
0.4648
(0.73)
0.1184
4.33
1.4
(1.41)
(0.19)
(2.95)
1.06
Information Ratio
(0.06)
(0.02)
(0.08)
(0.02)
(0.03)
(0.08)
(0.07)
(0.01)
(0.15)
(0.02)
Value At Risk
(4.95)
(8.13)
(8.91)
(10.26)
(14.08)
(16.05)
(9.68)
(12.82)
(5.75)
(6.98)

Hoth Therapeutics Competition Performance Charts

Five steps to successful analysis of Hoth Therapeutics Competition

Hoth Therapeutics' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Hoth Therapeutics in relation to its competition. Hoth Therapeutics' competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Hoth Therapeutics in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Hoth Therapeutics' competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Hoth Therapeutics, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Hoth Therapeutics position

In addition to having Hoth Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Latest Gainers Thematic Idea Now

Latest Gainers
Latest Gainers Theme
Dynamically computed list of top equities currently sorted across major exchanges. The Latest Gainers theme has 188 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Latest Gainers Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Hoth Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Hoth Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Hoth Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Hoth Therapeutics Stock:
How To Invest In Hoth
Details
Is Hoth Stock a good investment?
Details
What is Hoth Therapeutics' Net Worth?
Details
Largest Pharmaceuticals Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out Hoth Therapeutics Correlation with its peers.
For more detail on how to invest in Hoth Stock please use our How to Invest in Hoth Therapeutics guide.
You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Is there potential for Pharmaceuticals market expansion? Will Hoth introduce new products? Factors like these will boost the valuation of Hoth Therapeutics. Market participants price Hoth higher when confident in its future expansion prospects. Understanding fair value requires weighing current performance against future potential. All the valuation information about Hoth Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Hoth Therapeutics is measured differently than its book value, which is the value of Hoth that is recorded on the company's balance sheet. Investors also form their own opinion of Hoth Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Hoth Therapeutics' true underlying value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Because Hoth Therapeutics' market value can be influenced by many factors that don't directly affect Hoth Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Technical
Analysis
Details
Please note, there is a significant difference between Hoth Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Hoth Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, Hoth Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY